Why is this study important?
The five-year durability of the Portico self-expanding valve was addressed at CRT 2024. This study is unique in that there was a 60% enrollment rate in women. There was a high number of small annulus patients enrolled as well (515 patients)
What question was the study supposed to answer?
There is a paucity of data on long-term follow-up of patients receiving these values. The study pooled data from Portico-1, the IDE trial, and Portico CAP. The study used core lab echo data and clinical follow-up in 1,464 high-risk and extreme-risk patients.
What did the study show?
The clinical events of mortality and stroke were similar to other cohorts of high-risk patients from transcatheter valve trials. There was a low rate of patient prosthesis mismatch, even in small annulus patients at five years (<4%). There was a sustained maintenance in gradients (6.9mmHg) at five years. There were low rates of valve failure at five years.
More trials will need to address this valve platform in intermediate and low-risk patients.
Other Specialist Resources for Peripheral Vascular Disease
Including recently published studies, coverage of late-breaking science, updates from clinical trials and registries, and complex case presentations.